View Annual Report - Jules Stein Eye Institute

More documents

Recommendations

Info

$ucla laser refractive center informed consent$

Events The 2011–2012 academic year brought exciting advances to the Jules Stein Eye Institute. Of special significance, Institute researchers are conducting safety studies investigating the use of embryonic stem cells on patients with Stargardt macular dystrophy and dry age-related macular degeneration. Advancing research is just one of the many ways the Jules Stein Eye Institute strives to preserve and restore vision. Legally Blind Patients Receive Stem Cell Transplants On July 12, 2011, surgeons at the Jules Stein Eye Institute began a safety study that involved injecting human embryonic stem cells for the first time into the eyes of legally blind patients. Both patients, one with Stargardt macular dystrophy and the other with dry age-related macular degeneration, underwent outpatient transplantation surgeries and recovered uneventfully, according to the lead surgeon, Steven D. Schwartz, MD, Ahmanson Professor of Ophthalmology and chief of the Retina Division. Dr. Schwartz is the principal investigator on two clinical trials, one for each eye disease. Each trial will include 12 patients who are legally blind and will determine the safety of stem cell therapy. The patients’ ability to tolerate the surgical procedure itself went well. Human embryonic stem cells can differentiate into any cell type. The stem cell-derived retinal pigment epithelial (RPE) cells that were transplanted during surgery were differentiated in Advanced Cell Technology, Inc. (ACT) labs. ACT is a leader in the field of regenerative medicine and has been working for the last decade on developing a stem cell therapy to treat eye diseases. Each patient received a relatively low dose of the transplanted RPE cells (50,000) into the subretinal space of the treated eye. The dosing of the first patients in these trials, which are being closely watched by scientists and stem cell therapy advocates around the world, was hailed by ACT company officials as an important milestone in the therapeutic use of stem cells and may pave the way for a new therapeutic approach to treating eye diseases. Currently, both eye diseases are untreatable. The dry form of macular degeneration, the most common form of the disease, is the leading cause of blindness in the developed world, especially among people over the age of 55. As many as 30 million people in the United States and Europe currently suffer from this disease, and the number of people affected is expected to double over the next 20 years as the population ages. Stargardt disease causes progressive vision loss, usually starting when patients are between 10 to 20 years of age. In both conditions, the layer of RPE cells located beneath the retina deteriorates and atrophies. These cells support, protect, and provide nutrition for lightsensitive photoreceptors in the eye. Over time, the death of the RPE cells and eventual loss of the photoreceptors can lead to blindness as central vision is gradually destroyed. Doctors are hoping the transplanted RPE cells will implant and begin functioning. Noted Robert Lanza, MD, chief scientific officer of ACT, “The great promise of human embryonic stem cells is finally being put to the test with the initiation of these two clinical trials. It’s time to start moving these exciting new stem cell therapies out of the laboratory and into the clinic.” Dr. Steven Schwartz peers into a microscope during surgery to transplant highly specialized cells derived from human embryonic stem cells into the eyes of the first patients enrolled in two clinical trials that are testing the promise of stem cell therapy. Highlights | Events 3
Institute Brings a Pediatric-Friendly Experience to the Surgical Area On May 16, 2012, Institute Director Bartly J. Mondino, MD, introduced the Jules Stein Play Room, a dedicated children’s space located on the surgical floor of the Institute, and noted, “Today we celebrate the expansion of a pediatric-friendly experience from our clinics to our surgical suites.” Knowing a visit to the doctor can be an intimidating process for a child, the Institute, in cooperation with committed partners, has taken steps to ease the process for pediatric patients undergoing ophthalmic surgery by introducing a new children’s play area as well as trained specialists to guide families through the operative procedure. Bright and lively, the Play Room is filled with books, toys, puzzles, educational flash cards, and blocks to entertain youngsters during consultation and prior to surgery. Through the generosity of Wyndham Worldwide and the Starlight Children’s Foundation, the Jules Stein Play Room also includes a Fun Center mobile entertainment unit that offers a gaming system, DVD player, and television. A young visitor enjoys the new Jules Stein Play Room located on the surgical floor of the Institute. 4 Highlights | Events The Jules Stein Eye Institute is also incorporating the Chase Child Life Program for pediatric patients and their families, which offers Child Life Specialists, personnel who are trained personnel to help children and their parents better cope with the surgical experience. Child Life Specialists lead tours of the surgical area and accompany patients into surgery. They support the family by answering questions and providing educational information and resources so that parents and children alike can know what to expect. It’s especially reassuring for pediatric patients to have the familiar face of their Child Life Specialist with them as they go into surgery, and it reduces the parents’ anxiety to know their child is feeling more secure at that vulnerable time. The Chase Child Life Program, a no-cost offering, will be available once a week with the goal of expanding the service into a daily program. Through the generous support of caring partners, JSEI’s pediatric patients will enjoy a more comforting surgical experience. Left to right: Alison Sadock, corporate accounts manager, Starlight Children’s Foundation; Amy Bullock, director, Chase Child Life Program, Mattel Children’s Hospital, UCLA; Dr. Bartly Mondino, director, JSEI; Marti Winer, vice president of event services, Wyndham Worldwide; Mary Falvey, executive vice president, chief human resources officer, Wyndham Worldwide; Shannon O’Kelley, chief operating officer, UCLA Hospital System; Christine Archuleta, child life specialist, UCLA Operating Room Services; Paul Falcone, chief human resources officer, Starlight Children’s Foundation; Jacqueline Hart-Ibrahim, global chief executive officer, Starlight Children’s Foundation.
Page 1 and 2: Jules Stein Eye Institute ANNUAL RE
Page 3 and 4: ii Jules and Doris Stein The legacy
Page 5 and 6: iv Board of Trustees Board of Trust
Page 7 and 8: vi Jules Stein Mission Statement Th
Page 9: 2 Highlights Dear Friends, I am ple
Page 13 and 14: Honors Each year, as part of their
Page 15 and 16: Research Research is a key componen
Page 17 and 18: Adaptive Robotics for Ocular Surger
Page 19 and 20: 17th Annual Vision Science Conferen
Page 21 and 22: Audrey and Jack Skirball continued
Page 23 and 24: The Ahmanson Foundation Awards Gran
Page 25 and 26: Major Gifts over $25,000 American G
Page 27 and 28: Jules Stein Chair in Ophthalmology
Page 29 and 30: Community Outreach Much of the Jule
Page 31 and 32: Vision Education Vision IN-School (
Page 33 and 34: anthony J. aldave, mD Associate Pro
Page 35 and 36: Richard s. Baker, mD Associate Prof
Page 37 and 38: 30 Faculty | Bok Dean Bok, PhD Doll
Page 39 and 40: Richard casey, mD Clinical Professo
Page 41 and 42: Joseph L. Demer, mD, PhD Leonard Ap
Page 43 and 44: Gordon L. Fain, PhD Distinguished P
Page 45 and 46: Joann a. Giaconi, mD Assistant Clin
Page 47 and 48: Robert alan Goldberg, mD Karen and
Page 49 and 50: michael B. Gorin, mD, PhD Harold an
Page 51 and 52: Gary N. holland, mD Jack H. Skirbal
Page 53 and 54: Wayne L. hubbell, PhD Jules Stein P
Page 55 and 56: sherwin J. Isenberg, mD Laraine and
Page 57 and 58: simon K. Law, mD, PharmD Associate
Page 59 and 60: colin a. mccannel, mD Associate Pro
Page 61 and 62:
Kevin m. miller, mD Kolokotrones Pr
Page 63 and 64:
Kouros Nouri-mahdavi, mD, msc Assis
Page 65 and 66:
stacy L. Pineles, mD Assistant Prof
Page 67 and 68:
David sarraf, mD Associate Clinical
Page 69 and 70:
hui sun, PhD Associate Professor of
Page 71 and 72:
Federico G. Velez, mD Assistant Cli
Page 73 and 74:
David s. Williams, PhD Jules and Do
Page 75 and 76:
68 Faculty INsTITuTe memBeRs BaseD
Page 77 and 78:
70 Faculty PROFessIONaL ReseaRch se
Page 79 and 80:
72 Faculty michael D. Olson, OD, Ph
Page 81 and 82:
74 Faculty Vicki chan, mD Associate
Page 84 and 85:
Programs
Page 86 and 87:
Nearly all the evaluation, diagnosi
Page 88 and 89:
Diabetic Eye Disease and Retinal Va
Page 90 and 91:
Orbital Disease Center The Orbital
Page 92 and 93:
Ophthalmic Photography Clinical Lab
Page 94 and 95:
Didactic Education Residents receiv
Page 96 and 97:
Fellowship in Cornea-External Ocula
Page 98 and 99:
Fellowship in Vitreoretinal Disease
Page 100 and 101:
Appendices
Page 102 and 103:
Assistant Clinical Professor of Oph
Page 104 and 105:
Educational Offerings Ophthalmology
Page 106 and 107:
Research Contracts and Grants Fisca
Page 108 and 109:
Longitudinal Studies of Ocular Comp
Page 110 and 111:
Biochemical and Genetic Analysis of
Page 112 and 113:
Age-Related Eye Disease Study II Em
Page 114 and 115:
Corneal Endothelial Cell Changes in
Page 116 and 117:
Genetics of Age-Related Maculopathy
Page 118 and 119:
PET/CT Imaging for Early Detection
Page 120 and 121:
Publications of the Full-Time Facul
Page 122 and 123:
Li X, Bykhovskaya Y, Haritunians T,
Page 124 and 125:
Kalyani PS, Holland GN, Fawzi AA, A
Page 126 and 127:
Dean AW, Glasgow BJ. Mass spectrome
Page 128 and 129:
Appendices | Publications of the Fu
Page 130 and 131:
The emblem of the Jules Stein Eye I
show all

View Annual Report - Jules Stein Eye Institute

Create successful ePaper yourself

Delete template?

Save as template?